Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Autores de IIS La Fe

• Rubén Iglesias Gómez

  Autor

• Raúl Méndez Ocaña

  Autor

• Tomás Palanques Pastor

  Autor

• Octavio Antonio Ballesta López

  Autor

• Concepción Borras Almenar

  Autor

• Juan Eduardo Megías Vericat

  Autor

• Eduardo López Briz

  Autor

• Isabel Font Noguera

  Autor

• Rosario Menéndez Villanueva

  Autor

• 

  José Andrés Román Ivorra

  Autor

• José Luis Poveda Andrés

  Autor

Grupos

• Farmacogenética

• Infecciones Respiratorias

• Reumatología

Abstract

To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis.

© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords

• COVID-19, critical care, education, evidence-based medicine, pharmacy, pulmonary medicine, virology